The exploration of anti-TIGIT agents in advanced ESCC has demonstrated promising potential, especially when combined with anti-PD-1/PD-L1 therapy, across various stages including late-line and first-line settings. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.